Biotest AG
Biotest AG: Biotest hosts first international symposium to increase awareness for cytomegalovirus infections
DGAP-News: Biotest AG
/ Key word(s): Miscellaneous
PRESS RELEASE Biotest hosts first international symposium to increase awareness for cytomegalovirus infections
Together with the scientific coordinators, Prof Juliàn de la Torre and Dr Piedad Ussetti, Biotest facilitated a two-day program featuring international key opinion leaders. At the event, newest scientific insights and options to prevent CMV infections in patients, who received a solid organ or a stem cell transplantation as well as in pregnant women with CMV infection were discussed. Delegates from 21 countries and 3 continents engaged in discussing and exchanging experiences during these symposium. During this meeting, a huge interest for the use of CMV hyperimmunoglobulins to prevent CMV-related complications was shown. Dr Piedad Ussetti presented new transplantation guidelines, which will influence the number of available organs in the future, thus increasing the number of patients potentially suffering from CMV-related complications. Biotest will build upon this successful first event and use the momentum to continue increasing the awareness for all treatment options and the use of CMV hyperimmunoglobulins. Biotest recently received approval in 12 selected attractive European markets. This will further increase the market potential and strengthen Biotest’s position for this life-saving and high margin product. By facilitating the international symposium, Biotest intends to increase awareness for the threat posed by CMV infections in immunocompromised patients. About Cytotect(R) CP Biotest About Biotest IR contact PR contact Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201 Disclaimer
17.12.2019 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |
Language: | English |
Company: | Biotest AG |
Landsteinerstraße 5 | |
63303 Dreieich | |
Germany | |
Phone: | 0 61 03 – 8 01-0 |
Fax: | 0 61 03 – 8 01-150 |
E-mail: | investor_relations@biotest.de |
Internet: | http://www.biotest.de |
ISIN: | DE0005227235, DE0005227201 |
WKN: | 522723, 522720 |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 937331 |
End of News | DGAP News Service |